Essex Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,159
| Closed | -$954K | – | 364 |
|
|
2023
Q3 | $954K | Sell |
1,159
-212
| -15% | -$167K | 0.16% | 208 |
|
|
2023
Q2 | $985K | Sell |
1,371
-595
| -30% | -$459K | 0.14% | 209 |
|
|
2023
Q1 | $1.62M | Sell |
1,966
-139
| -7% | -$105K | 0.23% | 136 |
|
|
2022
Q4 | $1.52M | Sell |
2,105
-4,115
| -66% | -$3.04M | 0.24% | 129 |
|
|
2022
Q3 | $4.29M | Sell |
6,220
-386
| -6% | -$243K | 0.68% | 36 |
|
|
2022
Q2 | $3.9M | Sell |
6,606
-285
| -4% | -$185K | 0.63% | 45 |
|
|
2022
Q1 | $4.81M | Buy |
6,891
+447
| +7% | +$283K | 0.6% | 48 |
|
|
2021
Q4 | $4.07M | Hold |
6,444
| – | – | 0.47% | 56 |
|
|
2021
Q3 | $3.9M | Buy |
6,444
+21
| +0.3% | +$13K | 0.48% | 57 |
|
|
2021
Q2 | $3.59M | Sell |
6,423
-421
| -6% | -$213K | 0.42% | 73 |
|
|
2021
Q1 | $3.24M | Sell |
6,844
-432
| -6% | -$210K | 0.39% | 76 |
|
|
2020
Q4 | $3.52M | Sell |
7,276
-222
| -3% | -$120K | 0.44% | 70 |
|
|
2020
Q3 | $4.2M | Sell |
7,498
-79
| -1% | -$47.9K | 0.6% | 29 |
|
|
2020
Q2 | $4.72M | Sell |
7,577
-6,647
| -47% | -$3.77M | 0.77% | 22 |
|
|
2020
Q1 | $6.95M | Buy |
14,224
+4,224
| +42% | +$1.74M | 1.41% | 8 |
|
|
2019
Q4 | $3.75M | Buy |
+10,000
| New | +$3.36M | 0.46% | 53 |
|
|
2018
Q4 | – | Sell |
-12,613
| Closed | -$5.1M | – | 520 |
|
|
2018
Q3 | $5.1M | Buy |
12,613
+4,509
| +56% | +$1.72M | 0.6% | 36 |
|
|
2018
Q2 | $2.8M | Buy |
8,104
+4,256
| +111% | +$1.33M | 0.35% | 87 |
|
|
2018
Q1 | $1.32M | Buy |
+3,848
| New | +$1.34M | 0.17% | 171 |
|
|
2017
Q1 | – | Sell |
-5,375
| Closed | -$1.97M | – | 367 |
|
|
2016
Q4 | $1.97M | Hold |
5,375
| – | – | 0.32% | 83 |
|
|
2016
Q3 | $2.16M | Hold |
5,375
| – | – | 0.35% | 72 |
|
|
2016
Q2 | $1.88M | Buy |
+5,375
| New | +$2.07M | 0.31% | 87 |
|
|
2015
Q4 | – | Sell |
-1,445
| Closed | -$672K | – | 326 |
|
|
2015
Q3 | $672K | Hold |
1,445
| – | – | 0.11% | 190 |
|
|
2015
Q2 | $737K | Sell |
1,445
-5,667
| -80% | -$2.77M | 0.11% | 197 |
|
|
2015
Q1 | $3.21M | Buy |
7,112
+761
| +12% | +$323K | 0.45% | 66 |
|
|
2014
Q4 | $2.6M | Buy |
6,351
+5,416
| +579% | +$2.13M | 0.38% | 69 |
|
|
2014
Q3 | $337K | Hold |
935
| – | – | 0.05% | 280 |
|
|
2014
Q2 | $264K | Sell |
935
-260
| -22% | -$77.1K | 0.04% | 313 |
|
|
2014
Q1 | $359K | Sell |
1,195
-489
| -29% | -$151K | 0.05% | 278 |
|
|
2013
Q4 | $464K | Buy |
1,684
+136
| +9% | +$39.1K | 0.07% | 277 |
|
|
2013
Q3 | $484K | Sell |
1,548
-56
| -3% | -$14.7K | 0.07% | 257 |
|
|
2013
Q2 | $361K | Buy |
+1,604
| New | +$374K | 0.06% | 252 |
|
Other funds holding REGN
Essex Investment Management's REGN Position: Q4 2023 in Review
Essex Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 1,159 shares — an estimated $954K sold.
Essex Investment Management first reported a position in REGN in Q2 2013 and held it in 32 quarters. The position peaked at $6.95M in Q1 2020. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.
- Essex Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
- Essex Investment Management sold 1,159 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $954K.
- Essex Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 32 quarters.
- Essex Investment Management's Regeneron Pharmaceuticals position peaked at $6.95M in Q1 2020.
- 1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.
Based on Essex Investment Management's 13F filing for Q4 2023, filed 8 Feb 2024.